Transplant Recipients and Anal Neoplasia Study: Design, Methods, and Participant Characteristics of a Prevalence Study
Brenda Maria Rosales, Julian Langton-Lockton, Alyssa M Cornall, Jennifer M Roberts, Richard J Hillman, Angela Claire Webster, Andrew E Grulich, Fengyi Jin, I Mary Poynten, Annabelle Farnsworth, Suzanne M Garland, Sepehr N Tabrizi
Transplantation Direct | LIPPINCOTT WILLIAMS & WILKINS | Published : 2019
Awarded by NHMRC
Awarded by Cancer Council NSW Strategic Research Partnership Program grant
A.E.G. has received honoraria and research funding from CSL Biotherapies, honoraria and travel funding from Merck, and sits on the Australian advisory board for the Gardasil HPV vaccine. S.M.G. has received advisory board fees and grant support from CSL and GlaxoSmithKline, and lecture fees from Merck, GlaxoSmithKline, and Sanofi Pasteur; in addition has received funding through her institution to conduct HPV vaccine studies for MSD and GlaxoSmithKline and is a member of the Merck Global Advisory Board as well as the Merck Scientific Advisory Committee for HPV. R.J.H. has received support from CSL Biotherapies and MSD. A.C.W. is a member of the NSW representative for the Renal Transplant Advisory Committee and a member of the NSW Transplant Advisory Committee. All other authors declare that they have no competing interests.The TAN Study is based on the Study of the Prevention of Anal Cancer (SPANC), from which it has received logistical support. The SPANC study is funded by a NHMRC program grant (568971) and a Cancer Council NSW Strategic Research Partnership Program grant (13-11). The TAN study has additionally received funding from the Sydney Medical School Foundation, University of Sydney and the AIN Studies account at St Vincent's Hospital, Sydney. Cytological testing materials are provided by Hologic (Australia) Pty Ltd.